Allied Market Research
Loading...
0
New
New
2022

Asia–Pacific Oncology Molecular Diagnostics Market, By Application (Colorectal Cancer, Hematological Cancer, Breast Cancer, Lung Cancer, and Others), Type (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Fluorescence In-situ Hybridization (FISH), Spectrometry, and Others), and End User (Hospitals, Reference Laboratories, and Others) - Global Opportunities and Industry Forecasts, 2022-2031

A06287
Pages: 204
May 2022 | 3590 Views
   
Author(s) : Vikita Thakur, Vidhya Wable , Onkar Sumant
Tables: 84
Charts: 49
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the

Request Now !

Asia-Pacific Oncology Molecular Diagnostics Market Insight 2022-2031

The Asia-Pacific oncology molecular diagnostics market was valued at $610.17 Million in 2021, and is projected to reach $1,241.00 Million by 2031, registering a CAGR of 7.3% from 2022 to 2031. Oncology molecular diagnostics methods are applied for the treatment of various kinds of cancers such as breast cancer, prostate cancer, colon cancer and others based at their molecular level .This methods are used for identification and screening of cancer cells by analyzing their biomolecules such as protein,  DNA or RNA .There  are several molecular diagnostics tests are performed by using blood sample, saliva and sample from tumor tissue for detection and measurement of specific genetic sequence of the normal cell and infected cells. Oncology molecular diagnostics help to perform rapid analysis and provide detailed information about disease, and it will help to further cancer treatment.

The COVID-19 outbreak has negatively impacted the Asia-Pacific oncology molecular diagnostics market, owing to decline in number of patient visits in hospitals and clinics for cancer diagnosis.

Increase in prevalence of different kinds of cancers, increase in geriatric population, and growth in biomarker identification system and changed lifestyle, as well as technological advancements in molecular diagnostics techniques accelerate the oncology molecular diagnostics market growth. Apart from this, the increased demand for rapid and accurate diagnosis, along with advancements in next generation sequencing (NGS) techniques, is contributing to the growth of the market. Furthermore, increased surge in awareness about personalized medication and rise in number of patients suffering from different type of cancers also boost market growth. The support of government and key players for the development of the advanced technologies for the diagnosis and management of cancer population also boost the Asia-Pacific oncology molecular diagnostics market growth.

Asia-Pacific-Oncology-Molecular-Diagnostics-Market

Get more information on this report : Request Sample Pages

Lack of healthcare insurance and less awareness among individuals regarding the benefits of skilled professionals for handling of the molecular diagnostics techniques which will impede the growth of the oncology molecular diagnostics market. Moreover, governments introduce programs for awareness about cancer to reduce the burden of cancer population, which create lucrative opportunities for key market players.

COVID-19 Impact on Asia-Pacific oncology molecular diagnostics market

Coronavirus (COVID-19) was discovered in December 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans.

After its discovery in Wuhan, the disease rapidly spread to other parts of the globe. Moreover, this virus causes various symptoms in patients, which range from common symptoms to serious symptoms. For instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement. Furthermore, the virus has high potential of lethality in geriatric population. On March 11, 2020, the World Health Organization made an assessment that COVID-19 can be characterized as pandemic. In addition, only a few vaccines received emergency approvals for COVID-19 prevention. Thus, social distancing is observed as the most important measure to stop the spread of this disease. Furthermore, to maintain social distancing, various countries across the world have adopted nationwide lockdowns.

The COVID-19 outbreak has negatively impacted the Asia-Pacific oncology molecular diagnostics market, owing to decline in number of patient visits in hospitals and clinics for cancer diagnosis. As hospitals and clinics are giving first priority to COVID-19 patients so the appointment for diagnosis of cancer and their treatment are cancelled, which has negatively impacted the Asia-Pacific oncology molecular diagnostics market.

COVID-19 condition has disturbed the health care system and management of cancer treatment is affected by these disruptions. For instance, according to the Clinical Laboratory data in Australia, it was estimated that number of cancer patient visits for diagnosis has decreased by 17.3 % in 2020. As per, the Lancet Oncology, in 2020, it was estimated that the number cancer patient visits in Asia-Pacific decreased by 46% and these reduction in numbers are marked between April-October 2020. Thus, decline in number of cancer patient visits for diagnosis has led to decline in demand for oncology molecular diagnostic products.

The Asia-Pacific oncology molecular diagnostics market is segmented based of application, by type, end user, and country. By application, it is segmented into colorectal, lung, hematological, breast, and others. By type, polymerase chain reaction (PCR), Next Generation Sequencing (NGS), Fluorescence In situ Hybridization (FISH), spectrometry and others.  By end-user, it is categorized into hospitals, reference laboratories, and others (research institutes and academic institutes).By country it is categorized into Australia, Vietnam, Indonesia, Philippines, Thailand, Malaysia, and rest of Asia-Pacific.

By Application Segment Review

By application, the market is divided into colorectal, lung, hematological, breast, and others. The other cancer segment holds the largest market share in 2021. Owing to increase in the prevalence of different type of cancer such as prostate cancer, gastric cancer, pancreas cancer among others across the world drive the growth of Asia-Pacific oncology molecular diagnostics market.

Asia–Pacific Oncology Molecular Diagnostics Market, By Application - Global Opportunities and Industry Forecasts, 2022-2031
By Application

Your browser does not support the canvas element.

Opioids segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By Type Segment Review

By type, the market is classified into polymerase chain reaction (PCR), Next Generation Sequencing (NGS), Fluorescence In situ Hybridization (FISH), spectrometry and others. The   polymerase chain reaction (PCR) has dominated market in 2021. Owing to it is increase in adoption of polymerase chain reaction (PCR) as it offers various advantages such as less time-consuming process, requires low concentration of sample for test and easy to handle.

Asia–Pacific Oncology Molecular Diagnostics Market, By Application - Global Opportunities and Industry Forecasts, 2022-2031
By Type

Your browser does not support the canvas element.

PCR Segment hold the dominant position and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By End User Segment Review

By end user, the Asia-Pacific oncology molecular diagnostics market is categorized into hospitals, reference laboratories and others (research institute and academic institute. The hospitals segment has dominated market in 2021. Owing to increase in number of cancer patients visits for diagnosis and treatment drives the growth of market in upcoming years.

Asia–Pacific Oncology Molecular Diagnostics Market, By Application - Global Opportunities and Industry Forecasts, 2022-2031
By End User

Your browser does not support the canvas element.

Hospital Segment hold the dominant position and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By Country Segment Review

By country, the oncology molecular diagnostics market is analyzed across Australia, Vietnam, Indonesia, Philippines, Thailand, Malaysia, Singapore and rest of Asia-Pacific. Rest of Asia-Pacific has dominated market in 2021, owing increase in adoption and acceptance for personalized medicine, up gradation of healthcare infrastructure, and higher investments for R&D. Furthermore, the increase in prevalence of cancer in this country is expected to boost the market growth in upcoming years.

Asia–Pacific Oncology Molecular Diagnostics Market, By Application - Global Opportunities and Industry Forecasts, 2022-2031
By Region

2031
Rest Of Asia Pacific 
Australia
Vietnam
Indonesia
Thailand
Philiipines
Malaysia
Singapore

Rest of Asia pacific region would exhibit the highest CAGR of 7.7% during 2020-2031.

Get more information on this report : Request Sample Pages

This report provides comprehensive competitive analysis and profiles of prominent market players such as Abbott Laboratories, BioMerieux, Amoy Dx, F.Hoffmann-LA Roche Ltd, Siemens Healthcares, Danaher Corporation, Diasorin SP, Thermo Fisher, Agilent Technologies Inc. and Sysmex Corporation.

Key Benefits for Stakeholders

  • The study provides an in-depth analysis of the Asia-Pacific oncology molecular diagnostics market with current trends and future estimations to elucidate the imminent investment pockets in the market.
  • The report provides a quantitative analysis from 2022 to 2031 to enable stakeholders to capitalize on prevailing Asia-Pacific oncology molecular diagnostics market opportunities.
  • Extensive analysis by technology, application, and end user help understand various trends and prevailing opportunities in the respective market.
  • Key players within the market are profiled in this report and their strategies are analyzed thoroughly, which predict the competitive outlook of global Asia-Pacific oncology molecular diagnostics market.
  • Quantitative analysis of the current market and forecasts would assist stakeholders to design business strategies accordingly.
  • Porter’s five forces analysis examines the competitive market structure and provides a deeper understanding of the influencing factors for entry and expansion.

Key Market Segments

  • By Application
    • Colorectal Cancer
    • Hematological Cancer
    • Breast Cancer
    • Lung Cancer
    • Other Cancers
  • By Type
    • Polymerase Chain Reaction (PCR)
    • Next Generation Sequencing (NGS)
    • Fluorescence In situ Hybridization (FISH)
    • Spectrometry
    • Others
  • By End User
    • Hospitals
    • Reference Laboratories
    • Others (Research Institute and Academic Institute)
  • By Country
    • Thailand
    • Vietnam
    • Singapore
    • Malaysia
    • Australia
    • Philippines
    • Indonesia
    • Rest of Asia-pacific Key Players
    • Abbott Laboratories
    • BioMerieux,
    • Amoy Dx,
    • F.Hoffmann-LA Roche Ltd,
    • Siemens Healthcares,
    • Danaher Corporation,
    • Diasorin SP,
    • Thermo Fisher,
    • Agilent Technologies Inc
    • Sysmex Corporation
    • Illumina Inc
    • Qiagen N.V
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Top player positioning, 2021
3.4.Porter’s five forces analysis
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in prevalence of cancer
3.5.1.2.Growth in funding by governments
3.5.1.3.Growth in biomarker identification

3.5.2.Restraints

3.5.2.1.Lack of skilled professionals
3.5.2.2.Stringent regulatory requirements for product approvals

3.5.3.Opportunity

3.5.3.1.Advancements in genomics and proteomics

3.5.4.Impact analysis
3.5.5.Physicians prescribing behaviors
3.5.6.CDx Reimbursements

3.6.Impact analysis of COVID-19 on the post-traumatic stress disorder treatment market

CHAPTER 4:ASIA-PACIFIC ONCOLOGY MOLECULAR DIGNOSTICS MARKET, BY APPLICATION

4.1.Overview

4.1.1.Market size and forecast

4.2.Colorectal cancer

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by Country

4.3.Hematological cancer

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by country

4.4.Breast cancer

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by Country

4.5.Lung cancer

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by Country

4.6.Others cancers

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by country

CHAPTER 5:ASIA-PACIFIC ONCOLOGY MOLECULAR DIGNOSTICS MARKET, BY TYPE

5.1.Overview

5.1.1.Market size and forecast

5.2.Polymerase Chain Reaction (Polymerase Chain Reaction (PCR)))

5.2.1.Market size and forecast, by country

5.3.Fluorescence in-situ hybridization (FISH)

5.3.1.Market size and forecast, by country

5.4.Next Generation Sequencing (NGS)

5.4.1.Market size and forecast, by country

5.5.Spectrometry

5.5.1.Market size and forecast, by country

5.6.Others

5.6.1.Market size and forecast, by country

CHAPTER 6:ASIA–PACIFIC ONCOLOGY MOLECULAR DIGNOSTICS MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospitals

6.2.1.Market size and forecast, by Country

6.3.Reference laboratories

6.3.1.Market size and forecast, by country

6.4.Others

6.4.1.Market size and forecast, by country

CHAPTER 7:ASIA–PACIFIC ONCOLOGY MOLECULAR DIGNOSTICS MARKET, BY COUNTRY

7.1.Overview

7.1.1.Key market trends and opportunities
7.1.2.Market size and forecast

7.2.Vietnam

7.2.1.Vietnam oncology molecular diagnostics market, by application
7.2.2.Vietnam oncology molecular diagnostics market, by type
7.2.3.Vietnam oncology molecular diagnostics market, by end user

7.3.Thailand

7.3.1.Thailand oncology molecular diagnostics market, by application
7.3.2.Thailand oncology molecular diagnostics market, by type
7.3.3.Thailand oncology molecular diagnostics market, by end user

7.4.Indonesia

7.4.1.Indonesia oncology molecular diagnostics market, by application
7.4.2.Indonesia oncology molecular diagnostics market, by type
7.4.3.Indonesia oncology molecular diagnostics market, by end user

7.5.Malaysia

7.5.1.Malaysia oncology molecular diagnostics, by application
7.5.2.Malaysia oncology molecular diagnostics, by type
7.5.3.Malaysia oncology molecular diagnostics, by end user

7.6.Australia

7.6.1.Australia oncology molecular diagnostics market, by application
7.6.2.Australia oncology molecular diagnostics market, by type
7.6.3.Australia oncology molecular diagnostics market, by end user

7.7.Philippines

7.7.1.Philippines oncology molecular diagnostics market, by application
7.7.2.Philippines oncology molecular diagnostics market, by type
7.7.3.Philippines oncology molecular diagnostics market, by end user

7.8.Singapore

7.8.1.Singapore oncology molecular diagnostics market, by application
7.8.2.Singapore oncology molecular diagnostics market, by type
7.8.3.Singapore oncology molecular diagnostics market, by end user

7.9.Rest of Asia-Pacific

7.9.1.Asia-Pacific oncology molecular diagnostics market, by application
7.9.2.Asia-Pacific oncology molecular diagnostics market, by type
7.9.3.Asia –pacific oncology molecular diagnostics market, by end user

CHAPTER 8:COMPETITION LANDSCAPE

8.1.Top winning strategies
8.2.Product mapping
8.3.Competitive dashboard
8.4.Competitive heat map
8.5.Key developments

8.5.1.Collaboration
8.5.2.Product Approval
8.5.3.Acquisition
8.5.4.Partnership
8.5.5.Product Launch
8.5.6.Product Expansion
8.5.7.Agreement

8.6.Top player positioning 2021

CHAPTER 9:COMPANY PROFILES

9.1.ABBOTT LABORATORIES.

9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Business performance

9.2.AGILENT TECHNOLOGIES, INC.

9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio
9.2.5.Business performance
9.2.6.Key strategic moves and developments

9.3.AMOY DIAGNOSTICS CO LTD

9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Key strategic moves and developments

9.4.BIOMÉRIEUX SA

9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product portfolio
9.4.5.Business performance
9.4.6.Key strategic moves and developments

9.5.DANAHER CORPORATION

9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.5.5.Business performance

9.6.DIASORIN SPA

9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Business performance

9.7.F. HOFFMANN-LA ROCHE LTD.

9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio
9.7.5.Business performance

9.8.ILLUMINA INC.

9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance
9.8.6.Key strategic moves and developments

9.9.QIAGEN N.V.

9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Business performance
9.9.6.Key strategic moves and developments

9.10.SYSMEX CORPORATION

9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
9.10.5.Business performance
9.10.6.Key strategic moves and developments

9.11.SIEMENS HEALTHINEERS

9.11.1.Company overview
9.11.2.Company snapshot
9.11.3.Operating business segments
9.11.4.Product portfolio
9.11.5.Business performance

9.12.THERMO FISHER SCIENTIFIC INC.

9.12.1.Company overview
9.12.2.Company snapshot
9.12.3.Operating business segments
9.12.4.Product portfolio
9.12.5.Business Performance
9.12.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020-2031($MILLION)
TABLE 02.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER BY COUNTRY, 2020–2031 ($MILLION)
TABLE 03.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR HEMATOLOGICAL CANCER, BY COUNTRY, 2020–2031 ($MILLION)
TABLE 04.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, BY COUNTRY, 2020–2031 ($MILLION)
TABLE 05.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2020-2031($MILLION)
TABLE 06.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER, BY COUNTRY 2020-2031($MILLION)
TABLE 07.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2020–2031 ($MILLION)
TABLE 08.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR POLYMERAE CHAIN REACTION (PCR), BY REGION, 2020–2031 ($MILLION)
TABLE 09.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR FLUORESCENCE IN SITU HYBIRDIZATION (FISH), BY COUNTRY, 2020–2031 ($MILLION)
TABLE 10.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR NEXT GENERATION SEQUENCING (NGS) , BY REGION, 2020–2031 ($MILLION)
TABLE 11.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR SPECTROMETRY, BY REGION, 2020–2031 ($MILLION)
TABLE 12.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2020–2031($MILLION)
TABLE 13.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020-2031($MILLION)
TABLE 14.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAS, BYCOUNTRY 2020-2031($MILLION)
TABLE 15.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2020-2031($MILLION)
TABLE 16.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, FOR OTHERS, BY COUNTRY, 2020-2031($MILLION)
TABLE 17.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2020-2031 (MILLION)
TABLE 18.VIETNAM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020-2031($MILLION)
TABLE 19.VIETNAM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2020-2031($MILLION)
TABLE 20.VIETNAM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022-2031($MILLION)
TABLE 21.THAILAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020-2031($MILLION)
TABLE 22.THAILAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2020-2031($MILLION)
TABLE 23.THAILAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020-2031($MILLION)
TABLE 24.INDONESIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020-2031($MILLION)
TABLE 25.INDONESIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2020-2031($MILLION)
TABLE 26.INDONESIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020-2031($MILLION)
TABLE 27.MALAYSIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020-2031($MILLION)
TABLE 28.MALAYSIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022-2031($MILLION)
TABLE 29.MALAYSIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022-2031($MILLION)
TABLE 30.AUSTRALIA ONCOLOGY MOLECULAR DIAGNOSTICS, BY APPLICATION, 2020-2031($MILLION)
TABLE 31.AUSTRALIA ONCOLOGY MOLECULAR DIAGNOSTICS, BY TYPE, 2020-2031($MILLION)
TABLE 32.AUSTRALIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020-2031($MILLION)
TABLE 33.PHILIPPINES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020-2031($MILLION)
TABLE 34.PHILIPPINES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2020-2031($MILLION)
TABLE 35.PHILIPPINES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020-2031($MILLION)
TABLE 36.SINGAPORE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020-2031 ($MILLION)
TABLE 37.SINGAPORE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2020-2031($MILLION)
TABLE 38.SINGAPORE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020-2031($MILLION)
TABLE 39.ASIA –PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020-2031($MILLION)
TABLE 40.ASIA –PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2020-2031($MILLION)
TABLE 41.ASIA –PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020-2031($MILLION)
TABLE 42.ABBOTT: COMPANY SNAPSHOT
TABLE 43.ABBOTT: OPERATING SEGMENTS
TABLE 44.ABBOTT: PRODUCT PORTFOLIO
TABLE 45.AGILENT: COMPANY SNAPSHOT
TABLE 46.AGILENT: OPERATING SEGMENTS
TABLE 47.AGILENT: PRODUCT PORTFOLIO
TABLE 48.AGILENT TECHNOLOGIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 49.AMOY DX: COMPANY SNAPSHOT
TABLE 50.AMOY DX: OPERATING SEGMENTS
TABLE 51.AMOY DX: PRODUCT PORTFOLIO
TABLE 52.AMOY DX: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 53.BIOMEREUX SA: COMPANY SNAPSHOT
TABLE 54.BIOMEREUX SA: OPERATING SEGMENTS
TABLE 55.BIOMEREUX SA: PRODUCT PORTFOLIO
TABLE 56.BIOMEREUX SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 57.DANAHER: COMPANY SNAPSHOT
TABLE 58.DANAHER: OPERATING SEGMENTS
TABLE 59.DANAHER: PRODUCT PORTFOLIO
TABLE 60.DIASORIN: COMPANY SNAPSHOT
TABLE 61.DIASORIN: OPERATING SEGMENTS
TABLE 62.DIASORIN: PRODUCT PORTFOLIO
TABLE 63.HOFFMANN: COMPANY SNAPSHOT
TABLE 64.HOFFMANN: OPERATING SEGMENTS
TABLE 65.HOFFMANN: PRODUCT PORTFOLIO
TABLE 66.ILLUMINA INC.: COMPANY SNAPSHOT
TABLE 67.ILLUMINA INC.: OPERATING SEGMENTS
TABLE 68.ILLUMINA INC.: PRODUCT PORTFOLIO
TABLE 69.ILLUMINA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 70.QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 71.QIAGEN N.V.: OPERATING SEGMENT
TABLE 72.QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 73.QIAGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 74.SYSMEX: COMPANY SNAPSHOT
TABLE 75.SYSMEX: OPERATING SEGMENTS
TABLE 76.SYSMEX: PRODUCT PORTFOLIO
TABLE 77.SYSMEX CORPORATION.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 78.SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
TABLE 79.SIEMENS HEALTHINEERS: OPERATING SEGMENTS
TABLE 80.SIEMENS HEALTHINEERS: PRODUCT PORTFOLIO
TABLE 81.THERMO FISHER: COMPANY SNAPSHOT
TABLE 82.THERMO FISHER: OPERATING SEGMENTS
TABLE 83.THERMO FISHER: PRODUCT PORTFOLIO
TABLE 84.THERMO FISHER SCIENTIFIC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 01.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2022
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2022
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2022
FIGURE 06.TOP PLAYER POSITIONING, 2021
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.MODERATE BARGAINING POWER OF BUYERS
FIGURE 09.MODERATE THREAT OF SUBSTITUTES
FIGURE 10.HIGH THREAT OF NEW ENTRANTS
FIGURE 11.MODERATE INTENSITY OF RIVALRY
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.TOP WINNING STRATEGIES, BY YEAR, 2018–2022
FIGURE 14.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2022 (%)
FIGURE 15.TOP WINNING STRATEGIES, BY COMPANY, 2018–2022
FIGURE 16.PRODUCT MAPPING OF TOP 12 KEY PLAYERS
FIGURE 17.COMPETITIVE DASHBOARD OF TOP 12 KEY PLAYERS
FIGURE 18.COMPETITIVE HEATMAP OF TOP 12 KEY PLAYERS
FIGURE 19.TOP PLAYER POSITIONING 2021
FIGURE 20.ABBOTT:NET SALES,2019-2021 ($MILLION)
FIGURE 21.ABBOTT: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 22.ABBOTT: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 23.AGILENT:NET SALES,2019-2021 ($MILLION)
FIGURE 24.AGILENT: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 25.AGILENT: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 26.BIOMEREUX SA:NET SALES,2019-2021 ($MILLION)
FIGURE 27.BIOMEREUX SA: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 28.BIOMEREUX SA: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 29.DANAHER:NET SALES,2019-2021 ($MILLION)
FIGURE 30.DANAHER: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 31.DANAHER: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 32.DIASORIN:NET SALES,2019-2021 ($MILLION)
FIGURE 33.DIASORIN: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 34.HOFFMANN:NET SALES,2019-2021 ($MILLION)
FIGURE 35.HOFFMANN: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 36.HOFFMANN: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 37.ILLUMINA INC: NET SALES, 2019–2021 ($MILLION)
FIGURE 38.ILLUMINA INC: REVENUE SHARE, BY PRODUCTS, 2021 (%)
FIGURE 39.ILLUMINA INC: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 40.QIAGEN N.V.: NET SALES, 2020–2021 ($MILLION)
FIGURE 41.QIAGEN N.V.: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 42.QIAGEN N.V.: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 43.SYSMEX:NET SALES,2019-2021 ($MILLION)
FIGURE 44.SIEMENS HEALTHINEERS: NET SALES, 2019–2021 ($MILLION)
FIGURE 45.SIEMENS HEALTHINEERS: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 46.SIEMENS HEALTHINEERS: REVENUE SHARE, BY REGION, 2021(%)
FIGURE 47.THERMO FISHER: NET SALES, 2019–2021 ($MILLION)
FIGURE 48.THERMO FISHER: NET SALES, BY SEGMENT 2021 ($MILLION)
FIGURE 49.THERMO FISHER: NET SALES BY REGION, 2020 ($MILLION)


 
 

According to perspectives of CXOs, the market for Asia-Pacific oncology molecular diagnostics is growing, owing to advancements in technology, development of radiotracers, rise in prevalence of various type of cancers, and growth in awareness toward benefits of early diagnosis in the market

In addition, increase in funding by governments, rise in awareness and acceptance of personalized medicines, and growth in biomarker identification accelerate growth of the market. However, lack of skilled professional and stringent regulatory requirements for approval of new molecular diagnostic techniques restrains the market. Furthermore, many medical diagnostic product manufacturing companies are investing in R&D for development of advanced oncology molecular diagnostics tests. Moreover, rise in well-equipped hospitals and clinics for treatment of cancer patients and surge in awareness among people regarding personalized medicines in the region are responsible for growth of the Asia-Pacific oncology molecular diagnostics market.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization

 Customization Request

Have a question?

 Speak With Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of Report?

 Request Sample
FREQUENTLY ASKED QUESTIONS?
 

A. The total market value of Asia-Pacific oncology molecular diagnostics market is $1,241.00 million in 2031.

A. Top companies such as Abbott Laboratories, Amoy Diagnostics Co Ltd, Danaher Corporation,Thermo Fisher Qiagen N.V. and Illumina Inc. held a high market position in 2020. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. The lungs cancer segment is the most influencing segment owing to advancements in R&D activities in the healthcare sector, increase in lung cancer population, advancements in the diagnostic products and the launch of new products.

A. The forcast period for Asia-Pacific oncology molecular diagnostics market is 2022 to 2031

A. The market value of Asia-Pacific oncology molecular diagnostics market in 2021 is $610.17 million.

A. The base year is 2020 in Asia-Pacific oncology molecular diagnostics market

A. Increase in the prevalence of different kinds of cancers, increase in geriatric population, and growth in biomarker identification system and changed lifestyle, as well as technological advancements in molecular diagnostics techniques are the key trends in the Asia-Pacific oncology molecular diagnostics market report.

A. Rest of Asia pacific is expected to exhibit the fastest growth rate of CAGR 7.7% due to the increase in adoption and acceptance for personalized medicine, up gradation of healthcare infrastructures.

A. Yes, the Asia-Pacific oncology molecular diagnostics market companies are profiled in the report.

A. Yes, the Asia-Pacific oncology molecular diagnostics market provides PORTER Analysis in the report.

RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $2,310
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $2,567
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $3,989
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $4,312
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $7,013
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2021–2030

Published in Feb 2022

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers